Table 1. Summary of VAC053 and VAC065... | Rockefeller University Press

Table 1.

Summary of VAC053 and VAC065 clinical trials and the IgG humoral immune response to R21/Matrix-M vaccination

Trial	Volunteer	Lineages (#)	IGHV3-30/33 (#)	IGHV3-30/33 relative abundance (%)	Titer (µg/ml)
VAC053	14	23	21	90.8	64.2
	43	16	13	79.5	10.0
	50	33	13	93.9	19.7
	321	23	7	67.6	7.3
VAC065	1010	24	12	45.6	63.1
	1024	27	20	94.5	53.0
	1067	11	6	44.9	38.6
	1013	5	1	10.0	40.0
	1015	28	24	97.8	43.5
	1061	10	7	20.7	45.6

Trial	Volunteer	Lineages (#)	IGHV3-30/33 (#)	IGHV3-30/33 relative abundance (%)	Titer (µg/ml)
VAC053	14	23	21	90.8	64.2
	43	16	13	79.5	10.0
	50	33	13	93.9	19.7
	321	23	7	67.6	7.3
VAC065	1010	24	12	45.6	63.1
	1024	27	20	94.5	53.0
	1067	11	6	44.9	38.6
	1013	5	1	10.0	40.0
	1015	28	24	97.8	43.5
	1061	10	7	20.7	45.6

Titers against NANP₆ peptide were measured by indirect ELISA at day 63 (VAC053) and day 84 (VAC065).